Gem

The RNA Epitranscriptome of DNA Viruses

Brandon Tan, Shou-Jiang Gao
Michaela Ulrike Gack, Editor
DOI: 10.1128/JVI.00696-18

ABSTRACT

RNA modifications have generated much interest in the virology field, as recent works have shown that many viruses harbor these marks and modify cellular marks. The most abundant mRNA modification in eukaryotic cells, N6-methyladenosine (m6A), has been examined extensively at the genome-wide scale in both cellular and viral contexts. This Gem discusses the role of m6A in gene regulation and describes recent advancements in Kaposi's sarcoma-associated herpesvirus (KSHV) and simian virus 40 (SV40) research. We provide insights into future research related to m6A in DNA viruses.

INTRODUCTION

The flow of information orchestrated in myriad molecular events affords the cell with opportunities to maintain a steady state in response to diverse intracellular and extracellular signals. As an intermediate molecule between DNA and protein, mRNA offers a critical junction for the cell to tightly regulate the flow of information. With the half-life of mRNA being as short as 1 h, the cell needs to closely sense and regulate levels of mRNA to either replenish the existing pool of mRNA through transcription or remove mRNA through degradation (1). Additionally, the flow of information can be regulated by mechanisms such as alternative splicing and alternative polyadenylation, giving rise to different mRNA and protein isoforms from a single gene. Furthermore, regulation of mRNA is spatial, through controlled export from the nucleus into the cytoplasm. An apparent question is how the cell regulates these complex processes. Recent advances reveal that part of the answer might lie in mRNA modifications.

A plethora of mRNA modifications, including N6-methyladenosine (m6A), N1-methyladenosineosine (m1A), pseudouridine, and 5-methylcytosine (m5C), were unearthed in the 1970s (2–4). m6A is the most abundant modification on mRNA and has been shown to influence all the mRNA processes discussed above (5). In fact, early m6A studies on viruses, such as influenza virus (6), Rous sarcoma virus (7), and simian virus 40 (SV40) (8), excited the field of RNA modifications. However, owing to technological limitations, elucidating the topology and function of m6A remained elusive until the advent of m6A sequencing (m6A-seq) (9, 10). This technique enabled the profiling of the global m6A epitranscriptome and led to the identification of key characteristics of m6A methylation. Methylation has been found on about one in four transcripts, within RRACH motifs, and on the entire length of mRNA, with enrichment in the 3′ untranslated region (3′UTR) and the stop codon (9–11). Analogous genes in both humans and mice are methylated with 49% conservation (9), suggesting the occurrence of rapid evolutionary changes over time. Since methylation occurs cotranscriptionally, newly synthesized RNA often contains m6A methylation in intronic regions near splice junctions (12). With the discovery of two m6A demethylases, encoded by FTO and ALKBH5 (13, 14), a dynamic model of m6A has been proposed, which elevates the complexity of epitranscriptomics. This Gem provides an overview of the field of m6A epitranscriptomics and the cellular m6A machinery as well as their roles in regulating gene expression in the cell. We then focus on recent developments in DNA virus epitranscriptomics, with an emphasis on Kaposi's sarcoma-associated herpesvirus (KSHV) and SV40.

CELLULAR m6A MACHINERY AND ITS ROLE IN GENE REGULATION

Methyltransferases.The 70-kDa METTL3 protein was the first m6A methyltransferase to be identified and was known to be a subunit of a larger, ∼1-MDa complex that “writes” m6A onto mRNA (15, 16). It contains a binding pocket for the methyl group donor S-adenosylmethionine (SAM), adjacent to a methyltransferase domain. METTL3 exists in a heterodimer with METTL14, and depletion of either subunit significantly impairs methyltransferase activity in vitro (16, 17). This observation agrees with structural data showing that METTL14 has a catalytically inactive methyltransferase domain that enhances RNA binding of the METTL3-METTL14 dimer (18–21). Photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) and in vitro methylation studies show that these proteins bind to and methylate mRNA at RRACH motifs (17). Methylation of RNA occurs as it is being transcribed, with intronic regions containing METTL3-dependent m6A sites that promote splicing (12, 22). Under steady-state conditions, the methyltransferase complex is localized in the nucleus. However, METTL3 has been observed in the cytoplasm of lung cancer cells, mouse embryonic stem cells (mESC), and hepatitis C virus (HCV)-infected cells (23–25). In lung cancer cells, METTL3 is associated with eIF3 at the 5′UTR of methylated transcripts and promotes translation (24). METTL3-METTL14-dependent methylation is critical for HIV replication (26, 27). A single m6A site at the Rev responsive element (RRE) on the HIV genome has been proposed to enhance binding of Rev to the genome and to promote nuclear export of HIV RNA (27).

With the RRACH motif occurring every 86th nucleotide on the transcript, how the METTL3-METTL14 complex preferentially methylates sites on mRNA is not well understood. However, new evidence indicates that multiple subunits of the methyltransferase complex confer this specificity. Other identified subunits of the methyltransferase complex are WTAP (28, 29), RBM15/15B (30, 31), KIAA1429/VIRMA (28, 31, 32), HAKAI (31, 33), and ZC3H13 (25, 34). WTAP has no methyltransferase activity, yet knockdown of WTAP dramatically decreases the level of m6A in the cell. WTAP acts as a scaffold protein that recruits METTL3-METTL14 to nuclear speckles (28, 29). RBM15/15B is associated with the methyltransferase complex and required for methylation of the long noncoding RNA (lncRNA) Xist in humans. RBM15/15B regulates neuronal function and sex determination in Drosophila (30, 34). KIAA1429/VIRMA is important for methylation at the 3′UTR and is associated with the polyadenylation factors CPSF5 and CPSF6, hinting at a possible role of m6A in the selection of polyadenylation sites (32).

Knockdown of ZC3H13 in mouse embryonic stem cells and a Drosophila cell line resulted in reduced levels of m6A in the 3′UTR and increased intron retention (25, 34). Knuckles et al. demonstrated that ZC3H13 is required for the interaction between RBM15 and the rest of the methyltransferase complex, through WTAP, and that ZC3H13 regulates Drosophila sex determination by affecting alternative splicing of Sxl (34). Wen et al. showed that depletion of ZC3H13 causes other subunits of the methyltransferase complex, such as METTL3, METTL14, VIRMA, HAKAI, and WTAP, to relocalize to the cytoplasm and that ZC3H13 is important in regulating mESC self-renewal (25).

An additional methyltransferase, METTL16, methylates the 3′UTR of mRNA and U6 snRNA and regulates SAM levels in the cell by affecting splicing and intron retention of SAM synthetase (35, 36). However, METTL16 is unlikely to be associated with the METTL3-METTL14 complex, as it mediates methylation at UACm6AGAGAA motifs and depends on a hairpin structure for its activity (35, 36). Our knowledge of m6A biology prior to this study was limited to RRACH motifs, which make up 20 to 60% of all motifs found within m6A peaks (10). Hence, further elucidation of the topology and roles of these non-RRACH m6A sites in the cell is warranted.

m6A demethylases.There are currently two known demethylases in mammals that can reverse the m6A mark (FTO and ALKBH5), and they belong to the family of Fe2+/alpha-ketoglutarate-dependent dioxygenases. FTO was recently shown to demethylate N6,2′-O-dimethyladenosine (m6Am), suggesting that FTO may remove both m6A and m6Am (37, 38). Both FTO and ALKBH5 are localized to nuclear speckles (13, 14), though FTO can shuttle between the cytoplasm and the nucleus in rat neurons under starvation conditions (39) and is mediated by XPO2 (40). FTO regulates splicing by demethylating intronic m6A sites (41). The demethylation activity of ALKBH5 is critical for nuclear export of mRNA and for splicing in spermatocytes (14, 42). Studies on the dynamic nature of m6A have been limited to nuclear functions, such as alternative splicing and nuclear export, which agrees with the predominantly nuclear localization of FTO and ALKBH5 in most cell models. It remains to be seen how the cell removes m6A/m6Am once methylated mRNA has left the nucleus.

m6A-binding proteins.YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2 are part of the YTH domain family of m6A-binding proteins (43). YTHDF1, YTHDF2, and YTHDF3 are most conserved and are predominantly cytoplasmic (43). YTHDF1 recruits translation initiation factors to mRNA to facilitate translation (44), YTHDF2 promotes deadenylation of methylated transcripts by the CCR4-NOT complex (45, 46), and YTHDF3 promotes either translation or degradation of transcripts by interacting with YTHDF1 or YTHDF2, respectively (47, 48). Despite differing functions, all three proteins bind to ∼40% of the total YTHDF target mRNAs (48). Interestingly, all three proteins have similar affinities for m6A on RNA (1 to 2 μM), and hence competition for m6A sites among the proteins may depend on other RNA-binding factors or the secondary structure of the RNA (49–52). How YTHDF proteins choose to bind preferentially to certain transcripts is unclear and warrants a systematic study. YTHDC1 is localized to the nucleus and plays a role in splicing, alternative polyadenylation, and nuclear export (53–55). The splice factor SRSF3 together with YTHDC1 promotes exon inclusion, whereas SRSF10 competes with SRSF3/YTHDC1 to promote exon skipping (55). YTHDC1-facilitated nuclear export occurs through two subunits: SRSF3 and NXF1 (53). YTHDC2 is a nucleocytoplasmic protein that favors translation and degradation of mRNA by associating with the small ribosomal subunit and XRN1, respectively (56–58). How YTHDC2 is regulated to have such contradictory functions is unknown. On the other hand, YTHDF1 and YTHDF2 promote translation and degradation by binding to different complexes (58). It is likely that these different proteins regulate translation and degradation at different phases of the mRNA life cycle. For example, YTHDF1 might recruit translation initiation factors to mRNA preceding the binding of YTHDC2 to mRNA in the ribosome.

Additional m6A-binding proteins have been discovered. eIF3 promotes cap-independent translation by binding to 5′UTR m6A sites (59), while IGF2BP1/2/3 proteins promote translation and stability of transcripts by binding to m6A sites (60). FMR1 also binds to m6A sites but has an undefined function (61, 62).

m6A IN INFECTION OF DNA VIRUSES

m6A enhances SV40 replication.By applying photo-cross-linking-assisted m6A sequencing (PA-m6A-seq), Tsai and colleagues found about 11 and 2 potential m6A sites in the late and early regions of SV40, respectively (63). They introduced silent mutations at some of these m6A sites, which caused decreases in viral gene expression and virion production. Both METTL3 and YTHDF2, as well as YTHDF3 (to a lesser extent), were shown to promote lytic replication. Inhibition of these enzymes by 3-deazaadenosine (3DAA), as shown by Tsai et al., may have a therapeutic effect for treating SV40 infection and polyomas. The significance of this finding can be extended to human polyomaviruses, including Merkel cell polyomavirus, BK virus, and JC virus (64). Understanding the effect of SV40 infection on the host cell epitranscriptome may shed light on new strategies for treating polyomas.

Role of m6A in KSHV life cycle.Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic virus etiologically associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and KSHV-induced cytokine syndrome (KICS) (65–68). KSHV infects diverse types of cells and establishes latency, but KSHV infection of mesenchymal stem cells transforms them into tumor cells with KS-like features (65, 69–74). During latency, only a few viral genes are expressed, chiefly LANA, vFLIP, and vCyclin, as well as a dozen microRNAs (miRNAs), all of which are essential for tumorigenesis (71, 75–81). In tumors, a small proportion of cells undergo constant lytic replication, with most viral genes being expressed, culminating in the release of virions. These spontaneously lytic cells contribute to a protumor microenvironment by secreting a viral homolog of human interleukin-6 (IL-6), vIL6, as well as inducing proinflammatory cytokines, such as oncostatin M, vascular endothelial growth factor (VEGF), and IL-6 (82–85). Like other herpesviruses, KSHV encodes lytic transcripts expressed in a temporal manner, characterized as immediate early, early, and late transcripts (86–88). Our knowledge of how the expression of these transcripts is regulated is limited, and we sought to determine if m6A is involved in KSHV lytic replication. We investigated the viral and cellular m6A and m6Am epitranscriptomes during the latent and lytic phases of the KSHV life cycle by using m6A-seq and by modulating the cellular m6A machinery.

The KSHV latent epitranscriptome is conserved among different cell types during latency.We examined the following five latently infected KSHV cell lines: BCBL1-R cells (PEL cells), KiSLK cells (renal cell carcinoma cells), KTIME cells (telomerase-immortalized microvascular endothelial cells), KMM cells (rat metanephric mesenchymal precursor cells), and KMSC cells (adipose tissue-derived mesenchymal stem cells). The topology of the latent KSHV epitranscriptome was remarkably conserved across all five types of cells. The latent locus (ORF71/72/73) was the most consistently methylated locus in these latently infected cells, indicating a potentially important role of m6A in viral latency (89).

The cellular epitranscriptome is remodeled during latent infection.Utilizing four pairs of latently infected and uninfected cells (KiSLK versus iSLK, KMM versus MM, KTIME versus TIME, and KMSC versus MSC), we investigated the effects of KSHV latency on the cellular epitranscriptome by m6A-seq. Overall, the number of methylated transcripts and m6A motifs did not change significantly after KSHV infection. However, we observed striking 5′UTR hypomethylation and 3′UTR hypermethylation of m6A following viral infection for three of the four pairs of cells (KiSLK versus iSLK, KMM versus MM, and KMSC versus MSC), all of which were transformed cells, while the only pair of cells (KTIME versus TIME) that did not have 5′UTR hypomethylation was untransformed (Fig. 1A). Since KMM and KMSC cells are primary cells transformed by KSHV, we chose these two cell types for further analysis of cellular pathways affected by m6A. Interestingly, the most enriched pathways are those that regulate KSHV latency and cellular transformation, such as cytoskeleton and extracellular matrix signaling, cell-cell junction signaling, Rho signaling, ILK signaling, Ephrin signaling, endocytosis, and protein ubiquitination pathways. These results indicate that the m6A epitranscriptome is dynamic and that KSHV might alter the distribution of m6A on cellular transcripts to promote viral latency and tumorigenesis. Further studies are needed to identify viral factors involved in altering the distribution of cellular m6A and the effect of 5′UTR hypomethylation/3′UTR hypermethylation on these transcripts.

FIG 1
FIG 1

(A) KSHV reprograms the cellular epitranscriptome during latency, causing 5′UTR hypomethylation and 3′UTR hypermethylation (89). (B) Regulation of SV40 and KSHV replication by m6A. The influence of m6A on key events during SV40 and KSHV viral replication is highlighted. In the nucleus, the methyltransferases METTL3 and METTL14 favor the accumulation of SV40 and KSHV transcripts (90, 92). YTHDC1 enhances splicing of KSHV RTA transcripts (92). In the cytoplasm, YTHDF2 mediates degradation of KSHV transcripts, leading to repression of viral replication (89). YTHDF2 and YTHDF3 promote viral replication in KSHV (90) and SV40 (63), through a noncanonical role of these proteins.

Role of m6A during KSHV lytic replication.When we profiled the viral m6A epitranscriptomes of renal carcinoma cells (KiSLK) and PEL cells (BCBL1-R), we found that almost every viral transcript (94 viral genes) contained one or more m6A sites. Interestingly, the KSHV epitranscriptomes from both the KiSLK and PEL cell lines were at least 70% conserved, indicating an important role for m6A in viral lytic replication, regardless of cell type. We investigated the function of m6A during viral lytic replication by knocking down YTHDF2 and found elevated levels of viral transcripts, proteins, and release of virions. Furthermore, we observed an increase in the half-life of viral transcripts after YTHDF2 knockdown, which is consistent with the reported role of YTHDF2 in promoting mRNA degradation. Specifically, YTHDF2 binds to and degrades viral transcripts and negatively impacts KSHV replication (Fig. 1B). Using RNA-binding protein immunoprecipitation and reverse transcriptase quantitative PCR (RIP-RT-qPCR), we also showed that YTHDF2 selectively binds to certain viral transcripts at 48 h post-lytic induction. Hence, YTHDF2 might be a novel restriction factor for KSHV lytic replication. A conflicting role for YTHDF2 was observed in a different study, as knockdown resulted in decreased levels of viral transcripts, proteins, and release of virions (Fig. 1B) (90). The reason for this disparity is unknown, even though both studies used similar cell types, methods of gene silencing, and experimental time points for viral induction. However, the proviral role of YTHDF2 observed in that study contradicts the observation that YTHDF2 mediates viral mRNA degradation. Although it is unusual, this noncanonical role was also observed in influenza virus and SV40 replication (63, 91). The mechanism behind this noncanonical role of YTHDF2 remains unknown. Since KSHV has a complex temporal lytic replication cycle, YTHDF2 and other reader proteins may prefer distinct sets of viral transcripts at different time points. Both studies probed YTHDF2 knockdown at a single time point in KSHV lytic reactivation. This problem is further exacerbated by the nonsynchronous nature of KSHV lytic replication. Until we can develop technologies such as rapid conditional knockdown of m6A-binding proteins or specific inhibitors, the effects of m6A on different classes of KSHV transcripts at different time points might remain elusive.

Another study, by Ye et al., showed that inhibition of methylation by use of 3DAA impaired lytic replication, whereas silencing of FTO slightly increased lytic replication (92). They showed that YTHDC1 promotes splicing of KSHV RTA, which is essential and sufficient for inducing lytic replication. RTA itself was shown to increase levels of m6A in the cell, which agrees with the abundance of methylated viral transcripts during lytic replication (Fig. 1B) (89, 90, 92). However, it is worth mentioning that 3DAA has unspecific activities, while FTO also acts on m6Am, both of which may confound the observed effects.

The cellular epitranscriptome is modified during lytic replication.Lytic replication affected the cellular m6A epitranscriptome in KiSLK and BCBL1-R cells in distinct ways. 5′UTR hypermethylation and 3′UTR hypomethylation were observed in KiSLK cells, whereas the opposites were seen in BCBL1-R cells. We noticed a higher level of KSHV host shutoff and endonuclease (SOX) activity, which degrades host mRNA, in BCBL1-R cells than in KiSLK cells, as reflected by the different percentages of mapped cellular reads. Pathway analysis of hypermethylated and hypomethylated genes from both cell lines identified those associated with KSHV replication, such as protein kinase A signaling, ILK signaling, extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling, phosphatidylinositol 3-kinase (PI3K)/AKT signaling, adipogenesis, and integrin signaling (93).

CONCLUDING REMARKS

Modern studies on m6A of DNA viruses provide evidence that m6A can either promote or attenuate viral (SV40 and KSHV) replication. Given that these viruses replicate in the nucleus, the cellular m6A machinery is expected to regulate viral transcripts in a fashion similar to that for cellular transcripts. Smaller viruses, such as SV40, have fewer m6A sites, which are likely critical for viral replication. Attenuating m6A on the transcripts of these viruses by inhibiting the methyltransferase complex or activating the demethylases FTO and ALKBH5 might decrease viral replication. In contrast, as a large virus, KSHV might utilize m6A in a transcript-specific and temporal manner, making it difficult to broadly place m6A as a proviral or antiviral factor. The multitude of m6A-binding proteins and their contrasting functions, such as in the case of YTHDF1 and YTHDF2, complicate this matter.

Our knowledge of the epitranscriptomics of DNA viruses is in its infancy, and only a few observations on the role of m6A in KSHV and SV40 replication have been made so far. Other posttranscriptional mRNA modifications, such as m1A, pseudouridine, and m5C, have been studied less in viral contexts and thus require further investigation (94–96). For KSHV, it is difficult to pinpoint if m6A has a clear proviral or antiviral role. Hence, the use of inhibitors targeting the cellular m6A machinery for treatment of viral replication might be challenging. In contrast, for small DNA viruses, such as SV40 and its closely related relatives, such as JC virus, BK virus, and Merkel cell polyomavirus, 3DAA or other methyltransferase inhibitors may be examined for antiviral activity. For KSHV-associated tumors, identification of viral latent proteins or miRNAs that mediate the reprogramming of the cellular epitranscriptome is of great interest. Defining the mechanism by which m6A mediates the dysregulated cellular pathways involved in tumorigenesis might lead to the identification of potential novel therapeutic targets.

ACKNOWLEDGMENTS

This work was supported in part by grants from the NIH (grants CA096512, CA124332, CA132637, CA177377, CA213275, DE025465, and CA197153) to Shou-Jiang Gao.

REFERENCES

  1. 1.↵
    1. Sharova LV,
    2. Sharov AA,
    3. Nedorezov T,
    4. Piao Y,
    5. Shaik N,
    6. Ko MS
    . 2009. Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA Res 16:45–58. doi:10.1093/dnares/dsn030.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Adams JM,
    2. Cory S
    . 1975. Modified nucleosides and bizarre 5′-termini in mouse myeloma mRNA. Nature 255:28–33. doi:10.1038/255028a0.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Desrosiers R,
    2. Friderici K,
    3. Rottman F
    . 1974. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A 71:3971–3975.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Desrosiers RC,
    2. Friderici KH,
    3. Rottman FM
    . 1975. Characterization of Novikoff hepatoma mRNA methylation and heterogeneity in the methylated 5′ terminus. Biochemistry 14:4367–4374. doi:10.1021/bi00691a004.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Boccaletto P,
    2. Machnicka MA,
    3. Purta E,
    4. Piatkowski P,
    5. Baginski B,
    6. Wirecki TK,
    7. de Crecy-Lagard V,
    8. Ross R,
    9. Limbach PA,
    10. Kotter A,
    11. Helm M,
    12. Bujnicki JM
    . 2018. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res 46:D303–D307. doi:10.1093/nar/gkx1030.
    OpenUrlCrossRef
  6. 6.↵
    1. Krug RM,
    2. Morgan MA,
    3. Shatkin AJ
    . 1976. Influenza viral mRNA contains internal N6-methyladenosine and 5′-terminal 7-methylguanosine in cap structures. J Virol 20:45–53.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Beemon K,
    2. Keith J
    . 1977. Localization of N6-methyladenosine in the Rous sarcoma virus genome. J Mol Biol 113:165–179. doi:10.1016/0022-2836(77)90047-X.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Lavi S,
    2. Shatkin AJ
    . 1975. Methylated simian virus 40-specific RNA from nuclei and cytoplasm of infected BSC-1 cells. Proc Natl Acad Sci U S A 72:2012–2016.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Dominissini D,
    2. Moshitch-Moshkovitz S,
    3. Schwartz S,
    4. Salmon-Divon M,
    5. Ungar L,
    6. Osenberg S,
    7. Cesarkas K,
    8. Jacob-Hirsch J,
    9. Amariglio N,
    10. Kupiec M,
    11. Sorek R,
    12. Rechavi G
    . 2012. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485:201–206. doi:10.1038/nature11112.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Meyer KD,
    2. Saletore Y,
    3. Zumbo P,
    4. Elemento O,
    5. Mason CE,
    6. Jaffrey SR
    . 2012. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell 149:1635–1646. doi:10.1016/j.cell.2012.05.003.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Xuan JJ,
    2. Sun WJ,
    3. Lin PH,
    4. Zhou KR,
    5. Liu S,
    6. Zheng LL,
    7. Qu LH,
    8. Yang JH
    . 2018. RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res 46:D327–D334. doi:10.1093/nar/gkx934.
    OpenUrlCrossRef
  12. 12.↵
    1. Louloupi A,
    2. Ntini E,
    3. Conrad T,
    4. Orom UAV
    . 2018. Transient N-6-methyladenosine transcriptome sequencing reveals a regulatory role of m6A in splicing efficiency. Cell Rep 23:3429–3437. doi:10.1016/j.celrep.2018.05.077.
    OpenUrlCrossRef
  13. 13.↵
    1. Jia GF,
    2. Fu Y,
    3. Zhao X,
    4. Dai Q,
    5. Zheng GQ,
    6. Yang Y,
    7. Yi CQ,
    8. Lindahl T,
    9. Pan T,
    10. Yang YG,
    11. He C
    . 2011. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 7:885–887. doi:10.1038/nchembio.687.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Zheng G,
    2. Dahl JA,
    3. Niu Y,
    4. Fedorcsak P,
    5. Huang CM,
    6. Li CJ,
    7. Vagbo CB,
    8. Shi Y,
    9. Wang WL,
    10. Song SH,
    11. Lu Z,
    12. Bosmans RP,
    13. Dai Q,
    14. Hao YJ,
    15. Yang X,
    16. Zhao WM,
    17. Tong WM,
    18. Wang XJ,
    19. Bogdan F,
    20. Furu K,
    21. Fu Y,
    22. Jia G,
    23. Zhao X,
    24. Liu J,
    25. Krokan HE,
    26. Klungland A,
    27. Yang YG,
    28. He C
    . 2013. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell 49:18–29. doi:10.1016/j.molcel.2012.10.015.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Bokar JA,
    2. Rath-Shambaugh ME,
    3. Ludwiczak R,
    4. Narayan P,
    5. Rottman F
    . 1994. Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J Biol Chem 269:17697–17704.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Bokar JA,
    2. Shambaugh ME,
    3. Polayes D,
    4. Matera AG,
    5. Rottman FM
    . 1997. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA 3:1233–1247.
    OpenUrlAbstract
  17. 17.↵
    1. Liu J,
    2. Yue Y,
    3. Han D,
    4. Wang X,
    5. Fu Y,
    6. Zhang L,
    7. Jia G,
    8. Yu M,
    9. Lu Z,
    10. Deng X,
    11. Dai Q,
    12. Chen W,
    13. He C
    . 2014. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol 10:93–95. doi:10.1038/nchembio.1432.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Huang J,
    2. Dong X,
    3. Gong Z,
    4. Qin LY,
    5. Yang S,
    6. Zhu YL,
    7. Wang X,
    8. Zhang D,
    9. Zou T,
    10. Yin P,
    11. Tang C
    . 14 March 2018. Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase. Protein Cell doi:10.1007/s13238-018-0518-7.
    OpenUrlCrossRef
  19. 19.↵
    1. Sledz P,
    2. Jinek M
    . 2016. Structural insights into the molecular mechanism of the m(6)A writer complex. Elife 5:e18434. doi:10.7554/eLife.18434.
    OpenUrlCrossRef
  20. 20.↵
    1. Wang P,
    2. Doxtader KA,
    3. Nam Y
    . 2016. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell 63:306–317. doi:10.1016/j.molcel.2016.05.041.
    OpenUrlCrossRef
  21. 21.↵
    1. Wang X,
    2. Feng J,
    3. Xue Y,
    4. Guan Z,
    5. Zhang D,
    6. Liu Z,
    7. Gong Z,
    8. Wang Q,
    9. Huang J,
    10. Tang C,
    11. Zou T,
    12. Yin P
    . 2016. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature 534:575–578. doi:10.1038/nature18298.
    OpenUrlCrossRef
  22. 22.↵
    1. Ke S,
    2. Pandya-Jones A,
    3. Saito Y,
    4. Fak JJ,
    5. Vagbo CB,
    6. Geula S,
    7. Hanna JH,
    8. Black DL,
    9. Darnell JE, Jr,
    10. Darnell RB
    . 2017. m(6)A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. Genes Dev 31:990–1006. doi:10.1101/gad.301036.117.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Gokhale NS,
    2. McIntyre ABR,
    3. McFadden MJ,
    4. Roder AE,
    5. Kennedy EM,
    6. Gandara JA,
    7. Hopcraft SE,
    8. Quicke KM,
    9. Vazquez C,
    10. Willer J,
    11. Ilkayeva OR,
    12. Law BA,
    13. Holley CL,
    14. Garcia-Blanco MA,
    15. Evans MJ,
    16. Suthar MS,
    17. Bradrick SS,
    18. Mason CE,
    19. Horner SM
    . 2016. N6-methyladenosine in Flaviviridae viral RNA genomes regulates infection. Cell Host Microbe 20:654–665. doi:10.1016/j.chom.2016.09.015.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Lin S,
    2. Choe J,
    3. Du P,
    4. Triboulet R,
    5. Gregory RI
    . 2016. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell 62:335–345. doi:10.1016/j.molcel.2016.03.021.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Wen J,
    2. Lv R,
    3. Ma H,
    4. Shen H,
    5. He C,
    6. Wang J,
    7. Jiao F,
    8. Liu H,
    9. Yang P,
    10. Tan L,
    11. Lan F,
    12. Shi YG,
    13. He C,
    14. Shi Y,
    15. Diao J
    . 2018. Zc3h13 regulates nuclear RNA m6A methylation and mouse embryonic stem cell self-renewal. Mol Cell 69:1028.e6–1038.e6. doi:10.1016/j.molcel.2018.02.015.
    OpenUrlCrossRef
  26. 26.↵
    1. Kennedy EM,
    2. Bogerd HP,
    3. Kornepati AV,
    4. Kang D,
    5. Ghoshal D,
    6. Marshall JB,
    7. Poling BC,
    8. Tsai K,
    9. Gokhale NS,
    10. Horner SM,
    11. Cullen BR
    . 2016. Posttranscriptional m(6)A editing of HIV-1 mRNAs enhances viral gene expression. Cell Host Microbe 19:675–685. doi:10.1016/j.chom.2016.04.002.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Lichinchi G,
    2. Gao S,
    3. Saletore Y,
    4. Gonzalez GM,
    5. Bansal V,
    6. Wang Y,
    7. Mason CE,
    8. Rana TM
    . 2016. Dynamics of the human and viral m(6)A RNA methylomes during HIV-1 infection of T cells. Nat Microbiol 1:16011. doi:10.1038/nmicrobiol.2016.11.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Schwartz S,
    2. Mumbach MR,
    3. Jovanovic M,
    4. Wang T,
    5. Maciag K,
    6. Bushkin GG,
    7. Mertins P,
    8. Ter-Ovanesyan D,
    9. Habib N,
    10. Cacchiarelli D,
    11. Sanjana NE,
    12. Freinkman E,
    13. Pacold ME,
    14. Satija R,
    15. Mikkelsen TS,
    16. Hacohen N,
    17. Zhang F,
    18. Carr SA,
    19. Lander ES,
    20. Regev A
    . 2014. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5′ sites. Cell Rep 8:284–296. doi:10.1016/j.celrep.2014.05.048.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Ping XL,
    2. Sun BF,
    3. Wang L,
    4. Xiao W,
    5. Yang X,
    6. Wang WJ,
    7. Adhikari S,
    8. Shi Y,
    9. Lv Y,
    10. Chen YS,
    11. Zhao X,
    12. Li A,
    13. Yang Y,
    14. Dahal U,
    15. Lou XM,
    16. Liu X,
    17. Huang J,
    18. Yuan WP,
    19. Zhu XF,
    20. Cheng T,
    21. Zhao YL,
    22. Wang X,
    23. Rendtlew Danielsen JM,
    24. Liu F,
    25. Yang YG
    . 2014. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res 24:177–189. doi:10.1038/cr.2014.3.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Patil DP,
    2. Chen CK,
    3. Pickering BF,
    4. Chow A,
    5. Jackson C,
    6. Guttman M,
    7. Jaffrey SR
    . 2016. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537:369–373. doi:10.1038/nature19342.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Horiuchi K,
    2. Kawamura T,
    3. Iwanari H,
    4. Ohashi R,
    5. Naito M,
    6. Kodama T,
    7. Hamakubo T
    . 2013. Identification of Wilms' tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. J Biol Chem 288:33292–33302. doi:10.1074/jbc.M113.500397.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Yue Y,
    2. Liu J,
    3. Cui X,
    4. Cao J,
    5. Luo G,
    6. Zhang Z,
    7. Cheng T,
    8. Gao M,
    9. Shu X,
    10. Ma H,
    11. Wang F,
    12. Wang X,
    13. Shen B,
    14. Wang Y,
    15. Feng X,
    16. He C,
    17. Liu J
    . 2018. VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov 4:10. doi:10.1038/s41421-018-0019-0.
    OpenUrlCrossRef
  33. 33.↵
    1. Ruzicka K,
    2. Zhang M,
    3. Campilho A,
    4. Bodi Z,
    5. Kashif M,
    6. Saleh M,
    7. Eeckhout D,
    8. El-Showk S,
    9. Li H,
    10. Zhong S,
    11. De Jaeger G,
    12. Mongan NP,
    13. Hejatko J,
    14. Helariutta Y,
    15. Fray RG
    . 2017. Identification of factors required for m(6) A mRNA methylation in Arabidopsis reveals a role for the conserved E3 ubiquitin ligase HAKAI. New Phytol 215:157–172. doi:10.1111/nph.14586.
    OpenUrlCrossRef
  34. 34.↵
    1. Knuckles P,
    2. Lence T,
    3. Haussmann IU,
    4. Jacob D,
    5. Kreim N,
    6. Carl SH,
    7. Masiello I,
    8. Hares T,
    9. Villasenor R,
    10. Hess D,
    11. Andrade-Navarro MA,
    12. Biggiogera M,
    13. Helm M,
    14. Soller M,
    15. Buhler M,
    16. Roignant JY
    . 2018. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes Dev 32:415–429. doi:10.1101/gad.309146.117.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Pendleton KE,
    2. Chen B,
    3. Liu K,
    4. Hunter OV,
    5. Xie Y,
    6. Tu BP,
    7. Conrad NK
    . 2017. The U6 snRNA m(6)A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell 169:824.e814–835.e814. doi:10.1016/j.cell.2017.05.003.
    OpenUrlCrossRef
  36. 36.↵
    1. Warda AS,
    2. Kretschmer J,
    3. Hackert P,
    4. Lenz C,
    5. Urlaub H,
    6. Hobartner C,
    7. Sloan KE,
    8. Bohnsack MT
    . 2017. Human METTL16 is a N(6)-methyladenosine (m(6)A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep 18:2004–2014. doi:10.15252/embr.201744940.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Mauer J,
    2. Luo X,
    3. Blanjoie A,
    4. Jiao X,
    5. Grozhik AV,
    6. Patil DP,
    7. Linder B,
    8. Pickering BF,
    9. Vasseur JJ,
    10. Chen Q,
    11. Gross SS,
    12. Elemento O,
    13. Debart F,
    14. Kiledjian M,
    15. Jaffrey SR
    . 2017. Reversible methylation of m(6)Am in the 5′ cap controls mRNA stability. Nature 541:371–375. doi:10.1038/nature21022.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Linder B,
    2. Grozhik AV,
    3. Olarerin-George AO,
    4. Meydan C,
    5. Mason CE,
    6. Jaffrey SR
    . 2015. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods 12:767–772. doi:10.1038/nmeth.3453.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Vujovic P,
    2. Stamenkovic S,
    3. Jasnic N,
    4. Lakic I,
    5. Djurasevic SF,
    6. Cvijic G,
    7. Djordjevic J
    . 2013. Fasting induced cytoplasmic Fto expression in some neurons of rat hypothalamus. PLoS One 8:e63694. doi:10.1371/journal.pone.0063694.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Gulati P,
    2. Avezov E,
    3. Ma M,
    4. Antrobus R,
    5. Lehner P,
    6. O'Rahilly S,
    7. Yeo GS
    . 2014. Fat mass and obesity-related (FTO) shuttles between the nucleus and cytoplasm. Biosci Rep 34:e00144. doi:10.1042/BSR20140111.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Bartosovic M,
    2. Molares HC,
    3. Gregorova P,
    4. Hrossova D,
    5. Kudla G,
    6. Vanacova S
    . 2017. N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3′-end processing. Nucleic Acids Res 45:11356–11370. doi:10.1093/nar/gkx778.
    OpenUrlCrossRef
  42. 42.↵
    1. Tang C,
    2. Klukovich R,
    3. Peng H,
    4. Wang Z,
    5. Yu T,
    6. Zhang Y,
    7. Zheng H,
    8. Klungland A,
    9. Yan W
    . 2018. ALKBH5-dependent m6A demethylation controls splicing and stability of long 3′-UTR mRNAs in male germ cells. Proc Natl Acad Sci U S A 115:E325–E333. doi:10.1073/pnas.1717794115.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Patil DP,
    2. Pickering BF,
    3. Jaffrey SR
    . 2018. Reading m(6)A in the transcriptome: m(6)A-binding proteins. Trends Cell Biol 28:113–127. doi:10.1016/j.tcb.2017.10.001.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Wang X,
    2. Zhao BS,
    3. Roundtree IA,
    4. Lu Z,
    5. Han D,
    6. Ma H,
    7. Weng X,
    8. Chen K,
    9. Shi H,
    10. He C
    . 2015. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 161:1388–1399. doi:10.1016/j.cell.2015.05.014.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Du H,
    2. Zhao Y,
    3. He J,
    4. Zhang Y,
    5. Xi H,
    6. Liu M,
    7. Ma J,
    8. Wu L
    . 2016. YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun 7:12626. doi:10.1038/ncomms12626.
    OpenUrlCrossRef
  46. 46.↵
    1. Wang X,
    2. Lu Z,
    3. Gomez A,
    4. Hon GC,
    5. Yue Y,
    6. Han D,
    7. Fu Y,
    8. Parisien M,
    9. Dai Q,
    10. Jia G,
    11. Ren B,
    12. Pan T,
    13. He C
    . 2014. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505:117–120. doi:10.1038/nature12730.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Li A,
    2. Chen YS,
    3. Ping XL,
    4. Yang X,
    5. Xiao W,
    6. Yang Y,
    7. Sun HY,
    8. Zhu Q,
    9. Baidya P,
    10. Wang X,
    11. Bhattarai DP,
    12. Zhao YL,
    13. Sun BF,
    14. Yang YG
    . 2017. Cytoplasmic m(6)A reader YTHDF3 promotes mRNA translation. Cell Res 27:444–447. doi:10.1038/cr.2017.10.
    OpenUrlCrossRef
  48. 48.↵
    1. Shi H,
    2. Wang X,
    3. Lu Z,
    4. Zhao BS,
    5. Ma H,
    6. Hsu PJ,
    7. Liu C,
    8. He C
    . 2017. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res 27:315–328. doi:10.1038/cr.2017.15.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Luo S,
    2. Tong L
    . 2014. Molecular basis for the recognition of methylated adenines in RNA by the eukaryotic YTH domain. Proc Natl Acad Sci U S A 111:13834–13839. doi:10.1073/pnas.1412742111.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Theler D,
    2. Dominguez C,
    3. Blatter M,
    4. Boudet J,
    5. Allain FH
    . 2014. Solution structure of the YTH domain in complex with N6-methyladenosine RNA: a reader of methylated RNA. Nucleic Acids Res 42:13911–13919. doi:10.1093/nar/gku1116.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Xu C,
    2. Liu K,
    3. Ahmed H,
    4. Loppnau P,
    5. Schapira M,
    6. Min J
    . 2015. Structural basis for the discriminative recognition of N6-methyladenosine RNA by the human YT521-B homology domain family of proteins. J Biol Chem 290:24902–24913. doi:10.1074/jbc.M115.680389.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Xu C,
    2. Wang X,
    3. Liu K,
    4. Roundtree IA,
    5. Tempel W,
    6. Li Y,
    7. Lu Z,
    8. He C,
    9. Min J
    . 2014. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain. Nat Chem Biol 10:927–929. doi:10.1038/nchembio.1654.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Kasowitz SD,
    2. Ma J,
    3. Anderson SJ,
    4. Leu NA,
    5. Xu Y,
    6. Gregory BD,
    7. Schultz RM,
    8. Wang PJ
    . 2018. Nuclear m6A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development. PLoS Genet 14:e1007412. doi:10.1371/journal.pgen.1007412.
    OpenUrlCrossRef
  54. 54.↵
    1. Roundtree IA,
    2. Luo GZ,
    3. Zhang Z,
    4. Wang X,
    5. Zhou T,
    6. Cui Y,
    7. Sha J,
    8. Huang X,
    9. Guerrero L,
    10. Xie P,
    11. He E,
    12. Shen B,
    13. He C
    . 2017. YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs. Elife 6:e31311. doi:10.7554/eLife.31311.
    OpenUrlCrossRef
  55. 55.↵
    1. Xiao W,
    2. Adhikari S,
    3. Dahal U,
    4. Chen YS,
    5. Hao YJ,
    6. Sun BF,
    7. Sun HY,
    8. Li A,
    9. Ping XL,
    10. Lai WY,
    11. Wang X,
    12. Ma HL,
    13. Huang CM,
    14. Yang Y,
    15. Huang N,
    16. Jiang GB,
    17. Wang HL,
    18. Zhou Q,
    19. Wang XJ,
    20. Zhao YL,
    21. Yang YG
    . 2016. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Mol Cell 61:507–519. doi:10.1016/j.molcel.2016.01.012.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Hsu PJ,
    2. Zhu Y,
    3. Ma H,
    4. Guo Y,
    5. Shi X,
    6. Liu Y,
    7. Qi M,
    8. Lu Z,
    9. Shi H,
    10. Wang J,
    11. Cheng Y,
    12. Luo G,
    13. Dai Q,
    14. Liu M,
    15. Guo X,
    16. Sha J,
    17. Shen B,
    18. He C
    . 2017. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res 27:1115–1127. doi:10.1038/cr.2017.99.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Wojtas MN,
    2. Pandey RR,
    3. Mendel M,
    4. Homolka D,
    5. Sachidanandam R,
    6. Pillai RS
    . 2017. Regulation of m(6)A transcripts by the 3′→5′ RNA helicase YTHDC2 is essential for a successful meiotic program in the mammalian germline. Mol Cell 68: 374.e312–387.e312. doi:10.1016/j.molcel.2017.09.021.
    OpenUrlCrossRef
  58. 58.↵
    1. Kretschmer J,
    2. Rao H,
    3. Hackert P,
    4. Sloan KE,
    5. Hobartner C,
    6. Bohnsack MT
    . 2018. The m6A reader protein YTHDC2 interacts with the small ribosomal subunit and the 5′-3′ exoribonuclease XRN1. RNA 2018:rna.064238.117. doi:10.1261/rna.064238.117.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Meyer KD,
    2. Patil DP,
    3. Zhou J,
    4. Zinoviev A,
    5. Skabkin MA,
    6. Elemento O,
    7. Pestova TV,
    8. Qian SB,
    9. Jaffrey SR
    . 2015. 5′ UTR m(6)A promotes cap-independent translation. Cell 163:999–1010. doi:10.1016/j.cell.2015.10.012.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Huang H,
    2. Weng H,
    3. Sun W,
    4. Qin X,
    5. Shi H,
    6. Wu H,
    7. Zhao BS,
    8. Mesquita A,
    9. Liu C,
    10. Yuan CL,
    11. Hu YC,
    12. Huttelmaier S,
    13. Skibbe JR,
    14. Su R,
    15. Deng X,
    16. Dong L,
    17. Sun M,
    18. Li C,
    19. Nachtergaele S,
    20. Wang Y,
    21. Hu C,
    22. Ferchen K,
    23. Greis KD,
    24. Jiang X,
    25. Wei M,
    26. Qu L,
    27. Guan JL,
    28. He C,
    29. Yang J,
    30. Chen J
    . 2018. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol 20:285–295. doi:10.1038/s41556-018-0045-z.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Arguello AE,
    2. DeLiberto AN,
    3. Kleiner RE
    . 2017. RNA chemical proteomics reveals the N(6)-methyladenosine (m(6)A)-regulated protein-RNA interactome. J Am Chem Soc 139:17249–17252. doi:10.1021/jacs.7b09213.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Edupuganti RR,
    2. Geiger S,
    3. Lindeboom RGH,
    4. Shi H,
    5. Hsu PJ,
    6. Lu Z,
    7. Wang SY,
    8. Baltissen MPA,
    9. Jansen P,
    10. Rossa M,
    11. Muller M,
    12. Stunnenberg HG,
    13. He C,
    14. Carell T,
    15. Vermeulen M
    . 2017. N(6)-methyladenosine (m(6)A) recruits and repels proteins to regulate mRNA homeostasis. Nat Struct Mol Biol 24:870–878. doi:10.1038/nsmb.3462.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Tsai K,
    2. Courtney DG,
    3. Cullen BR
    . 2018. Addition of m6A to SV40 late mRNAs enhances viral structural gene expression and replication. PLoS Pathog 14:e1006919. doi:10.1371/journal.ppat.1006919.
    OpenUrlCrossRef
  64. 64.↵
    1. Davies SI,
    2. Muranski P
    . 2017. T cell therapies for human polyomavirus diseases. Cytotherapy 19:1302–1316. doi:10.1016/j.jcyt.2017.08.011.
    OpenUrlCrossRef
  65. 65.↵
    1. Cesarman E,
    2. Chang Y,
    3. Moore PS,
    4. Said JW,
    5. Knowles DM
    . 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186–1191. doi:10.1056/NEJM199505043321802.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Chang Y,
    2. Cesarman E,
    3. Pessin MS,
    4. Lee F,
    5. Culpepper J,
    6. Knowles DM,
    7. Moore PS
    . 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865–1869. doi:10.1126/science.7997879.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Soulier J,
    2. Grollet L,
    3. Oksenhendler E,
    4. Cacoub P,
    5. Cazals-Hatem D,
    6. Babinet P,
    7. d'Agay MF,
    8. Clauvel JP,
    9. Raphael M,
    10. Degos L,
    11. Sigaux F
    . 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276–1280.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. Uldrick TS,
    2. Wang V,
    3. O'Mahony D,
    4. Aleman K,
    5. Wyvill KM,
    6. Marshall V,
    7. Steinberg SM,
    8. Pittaluga S,
    9. Maric I,
    10. Whitby D,
    11. Tosato G,
    12. Little RF,
    13. Yarchoan R
    . 2010. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis 51:350–358. doi:10.1086/654798.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Carroll PA,
    2. Brazeau E,
    3. Lagunoff M
    . 2004. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 328:7–18. doi:10.1016/j.virol.2004.07.008.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Hong YK,
    2. Foreman K,
    3. Shin JW,
    4. Hirakawa S,
    5. Curry CL,
    6. Sage DR,
    7. Libermann T,
    8. Dezube BJ,
    9. Fingeroth JD,
    10. Detmar M
    . 2004. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36:683–685. doi:10.1038/ng1383.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    1. Jones T,
    2. Ye F,
    3. Bedolla R,
    4. Huang Y,
    5. Meng J,
    6. Qian L,
    7. Pan H,
    8. Zhou F,
    9. Moody R,
    10. Wagner B,
    11. Arar M,
    12. Gao SJ
    . 2012. Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest 122:1076–1081. doi:10.1172/JCI58530.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Lee MS,
    2. Yuan H,
    3. Jeon H,
    4. Zhu Y,
    5. Yoo S,
    6. Shi S,
    7. Krueger B,
    8. Renne R,
    9. Lu C,
    10. Jung JU,
    11. Gao SJ
    . 2016. Human mesenchymal stem cells of diverse origins support persistent infection with Kaposi's sarcoma-associated herpesvirus and manifest distinct angiogenic, invasive, and transforming phenotypes. mBio 7:e02109-15. doi:10.1128/mBio.02109-15.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Li Y,
    2. Zhong C,
    3. Liu D,
    4. Yu W,
    5. Chen W,
    6. Wang Y,
    7. Shi S,
    8. Yuan Y
    . 2018. Evidence for Kaposi sarcoma originating from mesenchymal stem cell through KSHV-induced mesenchymal-to-endothelial transition. Cancer Res 78:230–245. doi:10.1158/0008-5472.CAN-17-1961.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Wang HW,
    2. Trotter MW,
    3. Lagos D,
    4. Bourboulia D,
    5. Henderson S,
    6. Makinen T,
    7. Elliman S,
    8. Flanagan AM,
    9. Alitalo K,
    10. Boshoff C
    . 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36:687–693. doi:10.1038/ng1384.
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    1. Cai X,
    2. Lu S,
    3. Zhang Z,
    4. Gonzalez CM,
    5. Damania B,
    6. Cullen BR
    . 2005. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci U S A 102:5570–5575. doi:10.1073/pnas.0408192102.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Pfeffer S,
    2. Sewer A,
    3. Lagos-Quintana M,
    4. Sheridan R,
    5. Sander C,
    6. Grasser FA,
    7. van Dyk LF,
    8. Ho CK,
    9. Shuman S,
    10. Chien M,
    11. Russo JJ,
    12. Ju J,
    13. Randall G,
    14. Lindenbach BD,
    15. Rice CM,
    16. Simon V,
    17. Ho DD,
    18. Zavolan M,
    19. Tuschl T
    . 2005. Identification of microRNAs of the herpesvirus family. Nat Methods 2:269–276. doi:10.1038/nmeth746.
    OpenUrlCrossRefPubMedWeb of Science
  77. 77.↵
    1. Sarid R,
    2. Flore O,
    3. Bohenzky RA,
    4. Chang Y,
    5. Moore PS
    . 1998. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 72:1005–1012.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Staskus KA,
    2. Zhong W,
    3. Gebhard K,
    4. Herndier B,
    5. Wang H,
    6. Renne R,
    7. Beneke J,
    8. Pudney J,
    9. Anderson DJ,
    10. Ganem D,
    11. Haase AT
    . 1997. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71:715–719.
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Zhong W,
    2. Wang H,
    3. Herndier B,
    4. Ganem D
    . 1996. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A 93:6641–6646.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    1. Moody R,
    2. Zhu Y,
    3. Huang Y,
    4. Cui X,
    5. Jones T,
    6. Bedolla R,
    7. Lei X,
    8. Bai Z,
    9. Gao SJ
    . 2013. KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog 9:e1003857. doi:10.1371/journal.ppat.1003857.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Zhu Y,
    2. Ramos da Silva S,
    3. He M,
    4. Liang Q,
    5. Lu C,
    6. Feng P,
    7. Jung JU,
    8. Gao SJ
    . 2016. An oncogenic virus promotes cell survival and cellular transformation by suppressing glycolysis. PLoS Pathog 12:e1005648. doi:10.1371/journal.ppat.1005648.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Ensoli B,
    2. Sturzl M
    . 1998. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev 9:63–83. doi:10.1016/S1359-6101(97)00037-3.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Grundhoff A,
    2. Ganem D
    . 2004. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113:124–136. doi:10.1172/JCI200417803.
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    1. Liu C,
    2. Okruzhnov Y,
    3. Li H,
    4. Nicholas J
    . 2001. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. J Virol 75:10933–10940. doi:10.1128/JVI.75.22.10933-10940.2001.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    1. Miles SA,
    2. Martinez-Maza O,
    3. Rezai A,
    4. Magpantay L,
    5. Kishimoto T,
    6. Nakamura S,
    7. Radka SF,
    8. Linsley PS
    . 1992. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 255:1432–1434. doi:10.1126/science.1542793.
    OpenUrlAbstract/FREE Full Text
  86. 86.↵
    1. Jenner RG,
    2. Alba MM,
    3. Boshoff C,
    4. Kellam P
    . 2001. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol 75:891–902. doi:10.1128/JVI.75.2.891-902.2001.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Renne R,
    2. Zhong W,
    3. Herndier B,
    4. McGrath M,
    5. Abbey N,
    6. Kedes D,
    7. Ganem D
    . 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2:342–346. doi:10.1038/nm0396-342.
    OpenUrlCrossRefPubMedWeb of Science
  88. 88.↵
    1. Sun R,
    2. Lin SF,
    3. Staskus K,
    4. Gradoville L,
    5. Grogan E,
    6. Haase A,
    7. Miller G
    . 1999. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 73:2232–2242.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Tan B,
    2. Liu H,
    3. Zhang S,
    4. da Silva SR,
    5. Zhang L,
    6. Meng J,
    7. Cui X,
    8. Yuan H,
    9. Sorel O,
    10. Zhang SW,
    11. Huang Y,
    12. Gao SJ
    . 2018. Viral and cellular N(6)-methyladenosine and N(6),2′-O-dimethyladenosine epitranscriptomes in the KSHV life cycle. Nat Microbiol 3:108–120. doi:10.1038/s41564-017-0056-8.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Hesser CR,
    2. Karijolich J,
    3. Dominissini D,
    4. He C,
    5. Glaunsinger BA
    . 2018. N6-methyladenosine modification and the YTHDF2 reader protein play cell type specific roles in lytic viral gene expression during Kaposi's sarcoma-associated herpesvirus infection. PLoS Pathog 14:e1006995. doi:10.1371/journal.ppat.1006995.
    OpenUrlCrossRef
  91. 91.↵
    1. Courtney DG,
    2. Kennedy EM,
    3. Dumm RE,
    4. Bogerd HP,
    5. Tsai K,
    6. Heaton NS,
    7. Cullen BR
    . 2017. Epitranscriptomic enhancement of influenza A virus gene expression and replication. Cell Host Microbe 22:377.e375–386.e375. doi:10.1016/j.chom.2017.08.004.
    OpenUrlCrossRef
  92. 92.↵
    1. Ye F,
    2. Chen ER,
    3. Nilsen TW
    . 2017. Kaposi's sarcoma-associated herpesvirus utilizes and manipulates RNA N6-adenosine methylation to promote lytic replication. J Virol 91:e00466-17. doi:10.1128/JVI.00466-17.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Ye F,
    2. Lei X,
    3. Gao SJ
    . 2011. Mechanisms of Kaposi's sarcoma-associated herpesvirus latency and reactivation. Adv Virol 2011:193860. doi:10.1155/2011/193860.
    OpenUrlCrossRefPubMed
  94. 94.↵
    1. Dominissini D,
    2. Nachtergaele S,
    3. Moshitch-Moshkovitz S,
    4. Peer E,
    5. Kol N,
    6. Ben-Haim MS,
    7. Dai Q,
    8. Di Segni A,
    9. Salmon-Divon M,
    10. Clark WC,
    11. Zheng G,
    12. Pan T,
    13. Solomon O,
    14. Eyal E,
    15. Hershkovitz V,
    16. Han D,
    17. Dore LC,
    18. Amariglio N,
    19. Rechavi G,
    20. He C
    . 2016. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature 530:441–446. doi:10.1038/nature16998.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Yang X,
    2. Yang Y,
    3. Sun BF,
    4. Chen YS,
    5. Xu JW,
    6. Lai WY,
    7. Li A,
    8. Wang X,
    9. Bhattarai DP,
    10. Xiao W,
    11. Sun HY,
    12. Zhu Q,
    13. Ma HL,
    14. Adhikari S,
    15. Sun M,
    16. Hao YJ,
    17. Zhang B,
    18. Huang CM,
    19. Huang N,
    20. Jiang GB,
    21. Zhao YL,
    22. Wang HL,
    23. Sun YP,
    24. Yang YG
    . 2017. 5-Methylcytosine promotes mRNA export-NSUN2 as the methyltransferase and ALYREF as an m(5)C reader. Cell Res 27:606–625. doi:10.1038/cr.2017.55.
    OpenUrlCrossRef
  96. 96.↵
    1. Zhao BS,
    2. He C
    . 2015. Pseudouridine in a new era of RNA modifications. Cell Res 25:153–154. doi:10.1038/cr.2014.143.
    OpenUrlCrossRefPubMed
Back to top
Download PDF
Citation Tools
Print

Alerts
Email

KEYWORDS

m6A
N6-methyladenosine
m6Am
N6,2′-O-dimethyladenosine
epitranscriptome
KSHV
Kaposi's sarcoma-associated herpesvirus
SV40
simian virus 40
latency and lytic replication
5′UTR hypomethylation
3′UTR hypermethylation
YTHDF2
YTHDC1

Related Articles

Cited By...